Alveolar bone and the bisphosphonates

Area of Science:

• Oral and Maxillofacial Surgery
• Bone Biology
• Pharmacology

Background:

• Bisphosphonates are widely used to treat bone diseases.
• Osteonecrosis of the jaws (ONJ) is a known complication associated with bisphosphonate therapy.
• The specific mechanisms underlying ONJ development, particularly in the alveolar bone, require further elucidation.

Observation:

• Osteonecrosis of the jaws (ONJ) characteristically initiates at the alveolar bone.
• Differences in the microarchitecture and vascularization exist between alveolar bone and long bones.
• Bisphosphonates exhibit varying affinities and retention characteristics at different skeletal sites.

Findings:

• Alveolar bone's unique structure and function contribute to a higher susceptibility to bisphosphonate-induced osteonecrosis compared to long bones.
• Current understanding of ONJ pathogenesis involves factors such as altered bone remodeling, impaired angiogenesis, and local infection.
• The differential susceptibility is linked to the pharmacokinetics and pharmacodynamics of bisphosphonates within distinct bone microenvironments.

Implications:

• Dentists must be aware of the heightened risk of ONJ in patients using bisphosphonates, especially when managing periodontal disease.
• Understanding the site-specific effects of bisphosphonates is crucial for risk assessment and preventive strategies in dental practice.
• This knowledge aids in developing tailored management protocols for periodontal conditions in patients undergoing bisphosphonate therapy to minimize ONJ risk.